Overview

Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147

Status:
Completed
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
This Phase I clinical study is a randomized, double-blind, placebo-controlled, parallel-design study to thoroughly assess the safety profile and PK properties of J147 in healthy subjects. The study will include single ascending dose (SAD) in healthy young and elderly subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Abrexa Pharmaceuticals, Inc.
Collaborators:
IQVIA
Iqvia Pty Ltd